Ignite Creation Date:
2024-07-17 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06469268
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2024-05-29
Brief Title:
Development and Application Study of ePRO Software for Managing Cancer Patients Throughout the Treatment Period
Sponsor:
Shikai Wu
Organization:
Peking University First Hospital
Study Overview
Official Title:
Development and Application Study of ePRO Patient Reported Outcome Software for Managing Cancer Patients Throughout the Treatment Period
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
After receiving chemotherapy targeted therapy immunotherapy and other drug treatments tumor patients often experience various adverse reactions such as bone marrow suppression diarrhea pneumonia etc However due to the limited capacity of the hospital if patients who are discharged home cannot timely detect and deal with severe drug adverse reactions it will cause harm to their bodies and even threaten their life safety With the rapid development of network communication many foreign institutions have tried to develop ePRO software based on patient symptom reports This type of software is used to monitor drug adverse reactions and provide timely feedback to the attending physician for medical intervention Existing studies have shown that the application of this type of ePRO software significantly reduces the severity of drug adverse reactions on patients and significantly prolongs survival time
In this study the investigators plan to collaborate with Shenzhen 123 Digital Medical Group Co Ltd to design and develop a tumor ePRO software that allows outpatient treatment period patients who are discharged home to regularly self-assess the severity of drug adverse reactions and automatically feed back the scoring results to the departments monitoring center Doctors will make timely diagnosis and treatment based on each patients score results in order to maximize patient safety after treatment at home The results of this study will provide better follow-up care for tumor patients who are discharged home after anti-tumor treatment by significantly improving the safety of outpatient treatment period patients with tumors and thereby improving patient survival time and quality
In this study the investigators plan to collaborate with Shenzhen 123 Digital Medical Group Co Ltd to design and develop a tumor ePRO software that allows outpatient treatment period patients who are discharged home to regularly self-assess the severity of drug adverse reactions and automatically feed back the scoring results to the departments monitoring center Doctors will make timely diagnosis and treatment based on each patients score results in order to maximize patient safety after treatment at home The results of this study will provide better follow-up care for tumor patients who are discharged home after anti-tumor treatment by significantly improving the safety of outpatient treatment period patients with tumors and thereby improving patient survival time and quality
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None